These past few months have been a rush of fresh air. Aimovig. The drug we'd all been waiting for, was approved by the FDA. Now a few months later, we have Ajovy and Emgality in the mix as well. For a brief background, new research has pointed to CGRP being a main inhibitor for migraines, and the goal of these new drugs is to either block the receptor or weaken them. For months, I read through the trials and the testimonies. Those from individuals who had been a part of early testing and focused studies. Chronic migraine patients, just like me, who suffered from more than 15 migraine days each month. These people showed promising results. Or so they said. The average reduction was by 6 days, which is huge, even if you're suffering from a migraine every day. And then they talked about the common side effects. Irritation at the injection site. Constipation. That's all they list. What if I told you, as a migraine patient, the actual results show that only 15% of ...